Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience

    Research output: Contribution to journalReviewResearchpeer-review

  4. EJE PRIZE 2018: A gut feeling about glucagon

    Research output: Contribution to journalReviewResearchpeer-review

  5. Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hippocampal volume, cognitive functions, depression, anxiety, and quality of life in patients with Cushing's syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Thyroid peroxidase antibodies and prospective live birth rate: A cohort study of women with recurrent pregnancy loss

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Gudmundur Johannsson
  • Ulla Feldt-Rasmussen
  • Ida Holme Håkonsson
  • Henrik Biering
  • Patrice Rodien
  • Shigeyuki Tahara
  • Andrew Toogood
  • Michael Højby Rasmussen
  • REAL 2 Study Group
View graph of relations

OBJECTIVE: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative, developed for once-weekly administration. This study aimed to evaluate the safety of once-weekly somapacitan vs once-daily Norditropin®. Local tolerability and treatment satisfaction were also assessed.

DESIGN: 26-week randomized, controlled phase 3 safety and tolerability trial in six countries (Nbib2382939).

METHODS: Male or female patients aged 18-79 years with adult GH deficiency (AGHD), treated with once-daily GH for ≥6 months, were randomized to once-weekly somapacitan (n = 61) or once-daily Norditropin (n = 31) administered subcutaneously by pen. Both treatments were dose titrated for 8 weeks to achieve insulin-like growth factor I (IGF-I) standard deviation score (SDS) levels within the normal range, and then administered at a fixed dose. Outcome measures were adverse events (AEs), including injection site reactions; occurrence of anti-somapacitan/anti-GH antibodies and change in treatment satisfaction, assessed using the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9).

RESULTS: Mean IGF-I SDS remained between 0 and 2 SDS throughout the trial in both groups. AEs were mostly mild or moderate and transient in nature. The most common AEs were nasopharyngitis, headache and fatigue in both groups. More than 1500 somapacitan injections were administered and no clinically significant injection site reactions were reported. No anti-somapacitan or anti-GH antibodies were detected. The TSQM-9 score for convenience increased significantly more with somapacitan vs Norditropin (P = 0.0171).

CONCLUSIONS: In this 26-week trial in patients with AGHD, somapacitan was well tolerated and no safety issues were identified. Once-weekly somapacitan was reported to be more convenient than once-daily Norditropin.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume178
Issue number5
Pages (from-to)491-499
Number of pages9
ISSN0804-4643
DOIs
Publication statusPublished - May 2018

    Research areas

  • Adult, Aged, Cholelithiasis/chemically induced, Drug Administration Schedule, Dwarfism, Pituitary/blood, Female, Human Growth Hormone/administration & dosage, Humans, Male, Middle Aged, Serum Albumin/metabolism

ID: 55074469